JP2014517690A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517690A5
JP2014517690A5 JP2014510413A JP2014510413A JP2014517690A5 JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5 JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5
Authority
JP
Japan
Prior art keywords
noc
nucleic acid
multimer
igg2ah
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/036975 external-priority patent/WO2012154759A2/en
Publication of JP2014517690A publication Critical patent/JP2014517690A/ja
Publication of JP2014517690A5 publication Critical patent/JP2014517690A5/ja
Pending legal-status Critical Current

Links

JP2014510413A 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体 Pending JP2014517690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016204089A Division JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体

Publications (2)

Publication Number Publication Date
JP2014517690A JP2014517690A (ja) 2014-07-24
JP2014517690A5 true JP2014517690A5 (enExample) 2015-06-25

Family

ID=47139949

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014510413A Pending JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Country Status (8)

Country Link
US (3) US20140065113A1 (enExample)
EP (1) EP2707021B1 (enExample)
JP (5) JP2014517690A (enExample)
CN (2) CN103930439A (enExample)
AU (1) AU2012253652B2 (enExample)
CA (1) CA2835453A1 (enExample)
IL (1) IL229316B (enExample)
WO (1) WO2012154759A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
JP2014517690A (ja) * 2011-05-09 2014-07-24 ミネルバ バイオテクノロジーズ コーポレーション 遺伝子操作した成長因子変異体
IL240695B2 (en) * 2013-02-20 2024-03-01 Minerva Biotechnologies Corp Nme inhibitors and methods of using nme inhibitors
CN107076729A (zh) * 2014-10-16 2017-08-18 康希尔公司 变异体调用器
WO2021263227A2 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206129T1 (de) * 1989-10-18 2001-10-15 Us Health Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
PL202058B1 (pl) * 1999-08-09 2009-05-29 Merck Patent Gmbh Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002306921A1 (en) * 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
AU2005207960A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US8409577B2 (en) * 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
KR20140101876A (ko) * 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
KR20120025601A (ko) * 2009-06-11 2012-03-15 미네르바 바이오테크놀로지 코포레이션 줄기 세포 및 전구 세포를 배양하는 방법
US20130040845A1 (en) * 2010-02-16 2013-02-14 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP2686418A4 (en) * 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
JP2014517690A (ja) * 2011-05-09 2014-07-24 ミネルバ バイオテクノロジーズ コーポレーション 遺伝子操作した成長因子変異体

Similar Documents

Publication Publication Date Title
JP2014517690A5 (enExample)
US20240279303A1 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
JP7227290B2 (ja) キメラ抗原受容体、組成物及び方法
JP6965311B2 (ja) 二重特異的融合タンパク質
JP2017061471A5 (enExample)
CN102781960B (zh) Hsa相关组合物及使用方法
JP2019516663A5 (enExample)
JP2013541335A5 (enExample)
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
JP2022002528A (ja) 組織修復のための二重特異性治療用タンパク質
JP2015518479A5 (enExample)
JP2011525363A5 (enExample)
JP2014510518A (ja) Ｈｓａ関連組成物および使用方法
JP2017529059A5 (enExample)
WO2014178078A2 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
JP2014510519A5 (enExample)
JP2025078752A (ja) 腫瘍を標的にする合成アデノウイルスおよびその使用
EP2758072A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
JP2025137512A (ja) 新規に設計された共局在化依存性タンパク質スイッチを使用する超特異的細胞標的化
JP2022008506A (ja) 腫瘍抗原をコードする麻疹ウイルス
CN103342744B (zh) 一种血管新生蛋白及其应用
CN107298714A (zh) 一种双靶标融合蛋白及其制备方法和用途
SE0901565A1 (sv) Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013545440A (ja) マカカ・ファシキュラリス（Ｍａｃａｃａｆａｓｃｉｃｕｌａｒｉｓ）ＣＣＬ１７
CN112480262B (zh) 一种融合蛋白及其制备与应用